ASCO 2026 | CLIO-8221: a novel anti-HER2 dual payload ADC conjugated to TOP1i and ATRi

Timothy Yap • 4 Jun 2026

ASCO 2026

General CLIO-8221

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the background for a Phase I/II study (NCT07300943) of CLIO-8221, a HER2-targeted, dual-payload antibody-drug conjugate (ADC) conjugated to both topoisomerase 1 inhibitor (TOPi) and ATR inhibitor (ATRi), in patients with advanced HER2-expressing solid tumors. In preclinical models, CLIO-8221 has demonstrated potent anti-tumor activity and a good safety profile and is being evaluated as a monotherapy in the dose-escalation Phase I portion of the study across HER2-expressing solid tumors. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.